KR100750873B1 - A pharmaceutical composition comprising the extract of Rubiae Radix for treating or preventing allergic disease - Google Patents
A pharmaceutical composition comprising the extract of Rubiae Radix for treating or preventing allergic disease Download PDFInfo
- Publication number
- KR100750873B1 KR100750873B1 KR1020050066830A KR20050066830A KR100750873B1 KR 100750873 B1 KR100750873 B1 KR 100750873B1 KR 1020050066830 A KR1020050066830 A KR 1020050066830A KR 20050066830 A KR20050066830 A KR 20050066830A KR 100750873 B1 KR100750873 B1 KR 100750873B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- present
- cheoncho
- allergens
- pharmaceutical composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 69
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 12
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 235000013361 beverage Nutrition 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 7
- 235000013376 functional food Nutrition 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000013566 allergen Substances 0.000 abstract description 26
- 210000003630 histaminocyte Anatomy 0.000 abstract description 21
- 239000000203 mixture Substances 0.000 abstract description 19
- 230000028327 secretion Effects 0.000 abstract description 18
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 11
- 230000007815 allergy Effects 0.000 abstract description 11
- 230000003266 anti-allergic effect Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000013459 approach Methods 0.000 abstract description 3
- 102000006386 Myelin Proteins Human genes 0.000 abstract description 2
- 108010083674 Myelin Proteins Proteins 0.000 abstract description 2
- 210000005012 myelin Anatomy 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000000843 powder Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 9
- 208000010668 atopic eczema Diseases 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 230000000172 allergic effect Effects 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229920002055 compound 48/80 Polymers 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 206010002199 Anaphylactic shock Diseases 0.000 description 5
- 208000003455 anaphylaxis Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- -1 aceitol Chemical compound 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000123069 Ocyurus chrysurus Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000256215 Spongomorpha aeruginosa Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000009962 secretion pathway Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 천초근 추출물 및 상기 추출물을 포함하는 알레르기 질환의 예방 및 치료를 위한 약학조성물에 관한 것으로서, 더욱 상세하게는 본 발명에 따른 천초근 추출물은 비만세포로부터 알레르기 유발물질의 분비를 억제하는 효과를 나타내므로, 본 발명에 따른 천초근 추출물을 포함하는 조성물은 기존에 알레르기 치료의 증상을 완화하는 접근법에서 그 근본 원인을 치료함으로서 우수한 항알레르기 효과를 가질뿐더러 독성과 부작용이 없는 알레르기 질환의 예방 및 치료를 위한 의약품 또는 건강기능식품으로 유용하게 이용될 수 있다.The present invention relates to a medicinal composition for the prevention and treatment of cheoncho root extract and allergic diseases including the extract, more specifically, the cheoncho root extract according to the present invention has the effect of inhibiting the secretion of allergens from mast cells Therefore, the composition comprising the myelin extract according to the present invention by treating the root cause in the conventional approach to alleviate the symptoms of allergy treatment, not only has an excellent antiallergic effect, but also prevention of allergic diseases without toxicity and side effects and It can be usefully used as a medicine or health food for treatment.
천초근, 항알레르기, 비만세포, 의약품, 건강기능식품 Cheoncho Geun, Antiallergic, Mast Cell, Medicine, Health Food
Description
도 1은 알레르기를 유발하는 비만세포(RBL 2H3)에 대한 본 발명에 따른 천초근 추출물의 농도 의존적 억제효과를 나타낸 것이며,Figure 1 shows the concentration-dependent inhibitory effect of cheoncho root extract according to the present invention on allergen-induced mast cells (RBL 2H3),
도 2는 비만세포(RBL 2H3)의 알레르기 유발물질을 다른 물질로 자극할 경우 본 발명에 따른 천초근 추출물의 억제효과를 나타낸 것이다.Figure 2 shows the inhibitory effect of cheoncho muscle extract according to the present invention when stimulating allergens of mast cells (RBL 2H3) with other substances.
본 발명은 천초근 추출물 및 상기 추출물을 포함하는 알레르기 질환의 예방 및 치료를 위한 약학조성물에 관한 것이다.The present invention relates to a pharmaceutical composition for the prevention and treatment of cheoncho root extract and allergic diseases including the extract.
비만세포 및 혈중 호염구는 여러 가지 알레르기 질환 즉, 알레르기성 비염, 알레르기성 피부염, 천식, 음식 알레르기 및 아나필락틱 쇼크 등을 유발하는 체내 세포로 알려져 있다. 이들 세포는 세포표면에 알레르기를 유발하는 항체인 IgE에 대한 수용체(FcεRI)를 가지고 있고, 그것은 알레르기를 유발하는 물질(항원 혹은 알러젠으로 불림)에 의해 자극을 받아 자신이 가지고 있는 다양한 알레르기를 유발 시키는 물질을 세포 바깥으로 분비한다. Mast cells and blood basophils are known to be cells in the body causing various allergic diseases, such as allergic rhinitis, allergic dermatitis, asthma, food allergy and anaphylactic shock. These cells have receptors for IgE (FcεRI), an allergic antibody on the cell surface, which are stimulated by allergens (called antigens or allergens) to cause various allergies they have. Secrete the substance out of the cell.
알레르기를 치료하는 다양한 방법들이 존재하나, 대부분의 현대의 알레르기 치료는 그 원인을 없애기보다는 증상을 완화하는 방향으로 연구가 진행되어지고 있다. 대표적으로 알러젠에 의해 비만세포 등에서 분비된 히스타민이나 류코트리엔 등의 수용체에 대한 길항약들이 주를 이루고 이러한 약물들이 거대한 시장을 이루고 있다. 그러나 이러한 약물은 환자에게 투여 후 단기간 내에 내성을 보이기 때문에 일정기간 지난 후 혹은 반복 투여시 환자들의 증상을 호전시키지 못하는 경우가 많다. 따라서 본 발명에서는 비만세포 등에서 알레르기 물질분비를 원천적으로 차단함으로서 환자에게서 일어나는 항히스타민제등의 부작용이 없는 알레르기 치료제를 개발하고자 하였다. There are many ways to treat allergies, but most modern allergy treatments are being studied to alleviate the symptoms rather than eliminate the cause. Representatively, antagonists of histamine and leukotriene, which are secreted by mast cells from allergens, are dominant and these drugs form a huge market. However, since these drugs are resistant to patients within a short period of time after administration, they often do not improve symptoms after a certain period of time or repeated administration. Therefore, the present invention was intended to develop an allergy treatment without side effects such as antihistamines occurring in patients by blocking allergen secretion in mast cells and the like.
이 외에 다른 치료 방법으로 알레르기 환자가 앓고 있는 알레르기에 대한 알러젠을 규명 후 이를 소량씩 수년간 투여하여 그 알레르기를 점차 감소시키는 방법이 있다. 하지만 이 방법은 치료기간이 우선 수년이 걸리고, 아나필락틱 쇼크 등을 유발시킬 수 있다는 단점이 있다. 기타 DNA백신을 사용하는 방법, IgE가 비만세포의 수용체에 결합하는 것을 차단하는 치료법, 그리고 알레르기를 유발 하는 사이토카인인 IL4에 대한 항체 치료법등의 치료적 접근법이 있다. 하지만 이러한 접근법들은 비용이 많이 들거나 아직 완전히 그 치료효과가 규명되지 않았다는 점이 있다. In addition to other treatments, allergens for allergy sufferers to identify allergies and then administered in small amounts for several years there is a way to gradually reduce the allergy. This method, however, has the disadvantage that treatment takes several years and can cause anaphylactic shock. Therapeutic approaches include the use of other DNA vaccines, therapies that block IgE from binding to mast cell receptors, and the treatment of antibodies to IL4, an allergic cytokine. However, these approaches are expensive or have not yet been fully elucidated.
천초근(Rubiae radix)은 민간명으로 꼭두서니라고도 하는데, 예로부터 다양한 약리 효과가 있는 것으로 알려져 있다. 한방에서는 혈액순환을 원활하게 하여 어혈을 없애고, 지혈 작용을 하는 것으로 알려져 있으며, 관절이 저리고 아픈 것 등을 다스리는데 사용되고 있다. 또한, 최근에는 강심작용, 지혈촉진작용, 자궁수축작용, 이뇨작용, 항균작용 등이 보고되고 있다. Cheoncho Geun ( Rubia radix ) is a folk name, also known as marionette , has long been known to have various pharmacological effects. In oriental medicine, blood circulation is smoothed to remove fish blood and hemostasis is known, and joints are used to control pain and pain. In addition, recently, cardiac action, hemostatic action, uterine contraction action, diuretic action, antibacterial action and the like have been reported.
그러나, 천초근 추출물에 대한 항알레르기 효과에 대해서는 어떠한 개시나 교시된 바가 없다.However, no disclosure or teaching has been made about the antiallergic effect on the extract.
이에 본 발명자들은 알레르기성 비염, 천식 등 인간에게 불편함을 주거나 치명적인 다양한 알레르기를 유발하는 비만세포로부터 알레르기 유발물질의 분비를 차단함으로서 그 질환을 치료할 수 있는 물질을 비교적 안전성이 보장되어 있는 전통한방약재로부터 확보하고자 예의 노력한 결과, 본 발명에 따른 천초근 추출물이 한의학적 약리이론 이외에 비만세포로부터 알레르기 유발물질의 분비를 억제한다는 것을 확인함으로써 본 발명을 완성하게 되었다. Accordingly, the present inventors block the secretion of allergens from mast cells that cause discomfort to humans such as allergic rhinitis and asthma or cause various fatal allergens. As a result of intensive efforts to secure from the result, the present invention was completed by confirming that the extract of Cheoncho Geun according to the present invention inhibits the secretion of allergens from mast cells in addition to the herbal pharmacological theory.
결국 본 발명의 주된 목적은 알레르기성 비염, 천식 등 인간에게 불편함을 주거나 치명적인 다양한 알레르기를 유발하는 비만세포로부터 분비된 알레르기 유발물질의 분비를 차단하여 항알레르기 효과를 갖는 천초근 추출물을 제공하는데 있다. After all, the main object of the present invention is to provide a cheoncho root extract having an antiallergic effect by blocking the secretion of allergens secreted from mast cells causing various allergic or fatal allergic rhinitis, asthma, etc. .
또한, 본 발명의 다른 목적은 상기 천초근 추출물을 포함하는 알레르기 질환의 예방 및 치료를 위한 약학조성물을 제공하는데 있다.In addition, another object of the present invention to provide a pharmaceutical composition for the prevention and treatment of allergic diseases comprising the cheoncho root extract.
본 발명의 다른 목적은 항알레르기 효과를 가지는 천초근 추출물의 제조방법을 제공하는데 있다.It is another object of the present invention to provide a method for producing a cheoncho root extract having an antiallergic effect.
상기 목적을 달성하기 위하여, 본 발명은 알레르기 유발물질의 분비를 차단하여 항알레르기 효과를 나타내는 고련피 추출물을 제공한다.In order to achieve the above object, the present invention provides a bark extract showing an antiallergic effect by blocking the secretion of allergens.
본 발명에 따른 천초근 추출물은 물 및 메탄올, 에탄올, 부탄올 등과 같은 C1 내지 C4의 저급 알코올 및 이들의 혼합용매, 바람직하게는 에탄올에 가용한 추출물을 포함한다.Chuncho root extract according to the present invention includes water and C 1 to C 4 lower alcohols such as methanol, ethanol, butanol and the like, and a mixed solvent thereof, preferably extracts soluble in ethanol.
본 발명은 또한, (a) 천초근을 증류수로 세척하여 분쇄기로 분쇄하는 단계; (b) 상기 분쇄된 천초근을 열탕에서 가열하여 천초근 추출물을 얻는 단계; (c) 상기 천초근 추출물을 여과하여 상등액을 얻고 농축하는 단계; 및 (d) 상기 천초근 농축액을 동결건조하여 농축액 분말을 얻는 단계를 포함하는 알레르기 유발물질의 분비를 차단하여 항알레르기 효과를 나타내는 천초근 추출물의 제조방법을 제공한다.The present invention also comprises the steps of (a) washing the cheoncho root with distilled water and pulverizing with a grinder; (b) heating the pulverized cheoncho root in boiling water to obtain a cheoncho root extract; (c) filtrating the supernatant extract to obtain a supernatant and concentrating; And (d) freezing-drying the cheoncho root concentrate to obtain a concentrate powder, thereby providing a method for producing a cheoncho root extract that exhibits an antiallergic effect by blocking the secretion of allergens.
본 발명에 있어서, 상기 단계 (a)에서 물은 천초근 원료 100 g당 1 ℓ를 첨가하는 것을 특징으로 할 수 있고, 상기 단계 (b)에서 천초근을 100~120 ℃의 열탕에서 2~3시간 동안 가열하여 추출하는 것을 특징으로 할 수 있다.In the present invention, the water in the step (a) may be characterized in that 1 L per 100 g of the cheoncho root raw material is added, and in the step (b) the cheoncho root in the boiling water of 100 ~ 120 ℃ 2-3 It may be characterized in that the extraction by heating for a time.
본 발명은 또한, (a) 천초근을 저급 알코올에 침지시켜 초음파 추출기로 추출하여 알코올 추출물을 얻는 단계; (b) 상기 알코올 추출물의 상층액을 여과한 다음 농축하는 단계; 및 (c) 상기 천초근 농축액을 동결건조하여 농축액 분말을 얻는 단계를 포함하는 알레르기 유발물질의 분비를 차단하여 항알레르기 효과를 나타내 는 천초근 추출물의 제조방법을 제공한다.The present invention also comprises the steps of: (a) dipping the myelin root in lower alcohol to extract with an ultrasonic extractor to obtain an alcohol extract; (b) filtering the supernatant of the alcohol extract and then concentrating; And (c) freezing-drying the cheoncho root concentrate to obtain a concentrate powder, thereby providing a method for producing a cheoncho root extract that exhibits an antiallergic effect by blocking the secretion of allergens.
본 발명에 있어서, 상기 천초근은 천연 또는 인공 재배한 천초근의 지하부인 것을 특징으로 할 수 있고, 상기 단계 (a)에서 저급 알코올은 95% 에탄올인 것을 특징으로 할 수 있으며, 상기 단계 (a)는 2~4주 추출하는 것을 특징으로 할 수 있다.In the present invention, the cheoncho root may be characterized in that the subterranean portion of cheoncho root cultivated in natural or artificial, the lower alcohol in step (a) may be characterized in that 95% ethanol, the step (a ) May be characterized by extracting for 2-4 weeks.
이하 본 발명을 자세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명에 따른 천초근 추출물은 다음과 같이 수득될 수 있다.Cheoncho root extract according to the present invention can be obtained as follows.
본 발명의 천초근을 채집하여 건조하고 마쇄기로 분말화한 후, 천초근 시료 중량의 약 2배 내지 20배, 바람직하게는 약 5배 내지 10배에 달하는 부피의 물 및 메탄올, 에탄올, 부탄올 등과 같은 C1 내지 C4의 저급 알코올의 극성용매 또는 이들의 약 1:0.1 내지 1:10의 혼합비를 갖는 혼합용매로, 바람직하게는 물 또는 에탄올로 열수추출, 냉침추출, 환류냉각추출 또는 초음파추출 등의 추출방법을 사용하여 진공여과에 의해 상층액을 회수한 다음, 상기의 과정을 수차례 반복 수행하여 상층액을 모으고, 감압 농축하여 천초근 추출물을 수득할 수 있다.After collecting, drying and pulverizing the cheoncho root of the present invention, the volume of water and methanol, ethanol, butanol and the like of about 2 to 20 times, preferably about 5 to 10 times the weight of the sample A polar solvent of the same C 1 to C 4 lower alcohols or a mixed solvent having a mixing ratio of about 1: 0.1 to 1:10, preferably hot water extraction, cold extraction, reflux cooling extraction or ultrasonic extraction with water or ethanol The supernatant is recovered by vacuum filtration using an extraction method such as the above, and the above procedure is repeated several times to collect the supernatant, and concentrated under reduced pressure to obtain the cheoncho root extract.
본 발명은 상기의 제법으로 얻어진 천초근 추출물을 유효성분으로 함유하는 알레르기 질환의 예방 및 치료용 약학조성물을 제공한다.The present invention provides a pharmaceutical composition for the prevention and treatment of allergic diseases containing the cheoncho root extract obtained by the above method as an active ingredient.
또한, 천초근은 오랫동안 생약으로 사용되어 오던 약재로서 이로부터 추출된 본 발명에 따른 추출물 역시 독성 및 부작용 등의 문제가 없다.In addition, cheoncho root has been used as a herbal medicine for a long time, the extract according to the present invention extracted therefrom also does not have problems such as toxicity and side effects.
본 발명에 따른 알레르기 질환의 예방 및 치료용 약학조성물은 조성물 총 중 량에 대하여 상기 추출물을 0.1 내지 50 중량%로 포함한다.The pharmaceutical composition for preventing and treating allergic diseases according to the present invention comprises 0.1 to 50% by weight of the extract based on the total weight of the composition.
본 발명의 추출물을 포함하는 약학조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담채, 부형제 및 희석제를 더 포함할 수 있다.The pharmaceutical composition comprising the extract of the present invention may further comprise suitable tints, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
본 발명의 추출물의 약학적 투여 형태는 이들의 약학적으로 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다.Pharmaceutical dosage forms of the extracts of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds, as well as in a suitable collection.
본 발명에 따른 추출물을 포함하는 약학조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에이스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐리롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제, 예를 들면 전분, 칼슘카보네이트(calcium carbonate), 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구 투여를 위한 액상 제제로는 현탁액, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 웨텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Pharmaceutical compositions comprising extracts according to the invention, in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods. Can be formulated and used. Carriers, excipients and diluents that may be included in the composition comprising the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, aceitol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations may contain at least one excipient such as starch, calcium carbonate and sucrose in the extract. Or lactose, gelatin, or the like is mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서 본 발명의 추출물은 1일 0.0001 내지 100 ㎎/㎏, 바람직하게는 0.001 내지 100 ㎎/㎏으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.Preferred dosages of the extracts of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the preferred effect, the extract of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 0.001 to 100 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
본 발명은 알레르기 질환의 예방 효과를 나타내는 상기 추출물 및 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 건강기능식품을 제공한다.The present invention provides a health functional food comprising the extract and a food acceptable food supplement additive exhibiting a prophylactic effect of allergic diseases.
천초근 추출물을 첨가할 수 있는 식품으로는 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다.Examples of the food to which Cheoncho-geun extract can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.
또한, 알레르기 질환의 예방 효과를 목적으로 식품 또는 음료에 첨가될 수 있다. 이때, 식품 또는 음료 중의 상기 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다.It may also be added to foods or beverages for the purpose of preventing allergic diseases. At this time, the amount of the extract in the food or beverage may be added in 0.01 to 15% by weight of the total food weight, the health beverage composition may be added in a ratio of 0.02 to 5 g, preferably 0.3 to 1 g based on 100 ml. have.
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 외에 다른 성분에는 특별한 제한이 없으며, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등의 추가 성분을 함유할 수 있다. 상술한 천연 탄수화물의 예로는 모노사카라이드, 예를 들어 포도당, 과당 등; 디사카라이드, 예를 들어 말토오스, 수크로오스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 솔비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제인 타우마틴, 스테비아 추출물, 예를 들어 레바우디오시드 A, 글리시르히진 등; 및 합성 향미제, 예를 들어 사카린, 아스파르탐 등을 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The health functional beverage composition of the present invention is not particularly limited to other ingredients in addition to containing the extract as an essential ingredient in the indicated ratio, and may contain additional ingredients such as various flavoring agents or natural carbohydrates as in general beverages. . Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a flavoring agent other than the above-mentioned, a natural flavoring agent, taumartin, a stevia extract, for example, rebaudioside A, glycyrrhizin, etc .; And synthetic flavoring agents such as saccharin, aspartame and the like. The proportion of such natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 추출물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 및 천연 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 추출물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이때, 첨가제의 비율은 그다지 중요하지는 않지만 본 발명의 추출물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the extract of the present invention has various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, coloring and neutralizing agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective properties Colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the extracts of the present invention may contain flesh for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. At this time, the ratio of the additive is not very important, but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.
이하, 본 발명을 하기 실시예 및 실험예에 의거하여 보다 구체적으로 설명한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail based on the following Examples and Experimental Examples. These examples are only for illustrating the present invention, it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples.
실시예 1: 천초근 추출물의 제조Example 1: Preparation of Cheoncho Geun Extract
(1) 열탕 추출방법(1) boiling water extraction method
천초근 100 g을 증류수로 세척하여 분쇄기로 잘게 분쇄한 후, 물 1.0 ℓ를 첨가하여 환류냉각을 하면서 100~120 ℃의 열탕에서 2~3시간 동안 가열하여 추출한 다음, 이로부터 얻은 천초근 추출물을 여과하여 상등액을 회수하였다. 회수된 상등액은 농축기를 이용하여 농축하고, 상기 천초근 농축액은 -80 ℃에서 동결건조하여 천초근 추출물의 농축액 분말을 제조하였다.100 g of cheoncho root was washed with distilled water and finely pulverized by a pulverizer, and then extracted by heating for 2 to 3 hours in a boiling water at 100-120 ° C. while reflux cooling by adding 1.0 L of water. Filtration recovered the supernatant. The recovered supernatant was concentrated using a concentrator, and the cheoncho root concentrate was lyophilized at -80 ° C to prepare a concentrate powder of cheoncho root extract.
(2) 유기용매 추출방법(2) Organic Solvent Extraction Method
천초근을 95% 에탄올에 침지시켜 초음파 추출기로 2~3주 동안 추출하여 알코올 추출물을 얻은 후 상층액만을 분리하여 이를 거즈에 걸러 이물질을 제거하였다. 상기에서 얻은 알코올 추출물은 농축기를 이용하여 농축한 후 -80℃에서 동결건조하여 천초근 추출물의 농축액 분말을 제조하였다.Cheoncho root was immersed in 95% ethanol and extracted for 2 to 3 weeks using an ultrasonic extractor to obtain an alcohol extract. Then, only the supernatant was separated and filtered to remove foreign substances. The alcohol extract obtained above was concentrated using a concentrator, and then lyophilized at -80 ° C to prepare a concentrate powder of cheoncho root extract.
실험예 1: 비만세포에 대한 알레르기 유발물질 분비 억제효과 확인 Experimental Example 1: Confirmation of the inhibitory effect of allergens on mast cells
상기 실시예 1로부터 추출한 천초근 추출물이 체내에서 알레르기를 유발하는 비만세포로부터 알레르기 유발물질의 분비 억제효과를 조사하기 위하여, RBL-2H3 세포는 글루타민, 항생제와 15% 우혈청이 보충된 최소배지에서 배양하였다. In order to investigate the inhibitory effect of allergen-producing substances from the Chunchogeun extract extracted from Example 1 allergenic cells in the body, RBL-2H3 cells in a minimal medium supplemented with glutamine, antibiotics and 15% bovine serum Incubated.
분비실험을 하기 위하여 세포를 트립신에 의해 수거한 후, 24-well 배양기에 well당 200,000개의 세포를 25 ng/㎖ DNP-특이성 IgE와 같이 배양하였다. 상기 배양된 세포는 PIPES 완충액(25 mM PIPES, pH 7.2, 159 mM NaCl, 5 mM KCl, 0.4 mM MgCl2, 1 mM CaCl2, 5.6 mM glucose, 및 0.1% BSA)으로 세척한 다음, 항원을 첨가하기 전에 30분 동안 전배양 하였다. 전 배양 후 항원을 최종농도 25 ng/㎖로 첨가하여 자극을 유도하였다. After the cells were harvested by trypsin for secretion experiments, 200,000 cells per well were incubated with 25 ng / ml DNP-specific IgE in a 24-well incubator. The cultured cells were washed with PIPES buffer (25 mM PIPES, pH 7.2, 159 mM NaCl, 5 mM KCl, 0.4 mM MgCl 2 , 1 mM CaCl 2 , 5.6 mM glucose, and 0.1% BSA) and then the antigen was added. Pre-incubation for 30 minutes before. After preculture, the antigen was added at a final concentration of 25 ng / ml to induce stimulation.
알레르기 유도물질의 분비정도는 배지 중에 분비된 탈과립의 표식자인 hexosaminidase의 활성을 p-nitrophenyl-acetyl-β-D-glucosaminide로부터 유리된 p-nitrophenol의 양으로 결정하였다.The secretion of allergens was determined by the amount of p-nitrophenol liberated from p-nitrophenyl-acetyl-β-D-glucosaminide, a marker of degranulation.
(1) 항원에 의한 비만세포로부터 알레르기 유발물질의 분비에 대한 (1) the secretion of allergens from mast cells by antigen 천초근의Supernatural 억제효과 Inhibitory effect
도 1은 알레르기를 유발하는 비만세포 RBL-2H3(Funaba, M. et al., Cell Biol. Int., 27:879-85, 2003; Jeong, H.J. et al., Cytokine, 18:252-9, 2002)에 대한 본 발명에 따른 천초근 추출물의 농도 의존적 억제효과를 나타낸 것으로, 본 발명에 따른 천초근 추출물이 비만세포의 다양한 알레르기 유발물질의 분비를 농도 의존적으로 억제함을 확인할 수 있었다. 그 최고 분비의 50 %를 억제하는 천초근 추출물의 농도(IC50)는 약 34 ㎍/㎖로, 비교적 낮은 농도에서 높은 억제효과를 나타냈으며, 100 ㎍/㎖에서는 80 %이상 분비가 억제되었다. 1 shows allergen-induced mast cell RBL-2H3 (Funaba, M. et al., Cell Biol. Int., 27: 879-85, 2003; Jeong, HJ et al., Cytokine, 18: 252-9, It was shown that the concentration-dependent inhibitory effect of the cheoncho root extract according to the present invention for 2002), the cheoncho root extract according to the present invention concentration-dependently inhibit the secretion of various allergens of mast cells. The concentration of the extract of S. aeruginosa (IC 50 ), which inhibits 50% of its highest secretion, was about 34 μg / ml, indicating a high inhibitory effect at relatively low concentrations, and more than 80% of the secretion was suppressed at 100 μg / ml.
(2) Compound 48/80에 의한 비만세포로부터 알레르기 유발물질의 분비에 대한 천초근의 억제효과(2) Inhibitory Effect of Cheoncho-Geun on Secretion of Allergens from Mast Cells by Compound 48/80
도 2는 비만세포 RBL-2H3의 알레르기 유발물질을 다른 물질(compound 48/80)로 자극할 때 본 발명에 따른 추출물의 억제효과를 나타낸 것이다. 도 2에 나타난 바와 같이, compound 48/80에 의한 비만세포로부터 알레르기 유발물질의 분비 역시 천초근 추출물에 의해 저농도(IC50; 약 23.6 ㎍/㎖)에서 유의하게 억제되었으며, 100 ㎍/㎖에서는 분비가 80 %이상 억제되었다.Figure 2 shows the inhibitory effect of the extract according to the present invention when stimulating allergens of mast cells RBL-2H3 with other substances (compound 48/80). As shown in Figure 2, the secretion of allergens from mast cells by the compound 48/80 was also significantly inhibited at low concentrations (IC 50 ; about 23.6 ㎍ / ㎖) by cheoncho root extract, secreted at 100 ㎍ / ㎖ Was suppressed more than 80%.
이로부터 본 발명의 천초근 추출물은 비만세포의 다양한 분비경로를 모두 차단함으로서 알레르기 억제효과를 나타내는 것으로 확인할 수 있었다.From this, the cheoncho root extract of the present invention was confirmed to exhibit an allergic inhibitory effect by blocking all the various secretion pathways of mast cells.
실시예 3: 알레르기 동물 모델에서 항알레르기 효과 확인Example 3: Confirmation of antiallergic effect in allergic animal model
전신성 알레르기 반응성 아나필락틱 쇼크 동물모델은 compound 48/80을 마우스에 ㎏당 8 ㎎을 복강 내 투여함으로서 얻을 수 있었다. Compound 48/80 투여 한시간 전에 천초근 추출물을 투여하여 아나필락틱 쇼크 억제 효과를 확인하고, 그 결과는 표 1에 정리하였다.Systemic allergic reactive anaphylactic shock animal models were obtained by intraperitoneally administering compound 48/80 to mice at 8 mg / kg. One hour before the 48/80 compound administration, the extract was administered to confirm the anaphylactic shock inhibitory effect, the results are summarized in Table 1.
표 1에 나타난 바와 같이, 천초근 추출물은 그 반응이 억제되었으며 ㎏당 100 ㎎ 투여군에서 42.8 %가 억제되었고, ㎏당 300 ㎎ 투여군에서는 48.5 %가 억제되었다. 이로부터 본 발명의 천초근 추출물이 시험관에서 뿐 아니라 질병동물 모델에서도 높은 알레르기 질환을 억제하는 효과를 나타내는 것을 확인할 수 있었다.As shown in Table 1, the cheonchogeun extract was inhibited the reaction, 42.8% was suppressed in the 100 mg / kg administration group, 48.5% was inhibited in the 300 mg / kg administration group. From this, it was confirmed that the cheoncho root extract of the present invention exhibits the effect of suppressing high allergic diseases not only in vitro but also in disease animal models.
[표 1] Compound 48/80에 의해 유도된 전신성 아나필락틱 쇼크에 대한 천초근 추출물의 방어효과 Table 1 Protective Effect of Cheoncho-Geun Extract on Systemic Anaphylactic Shock Induced by Compound 48/80
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.The specific parts of the present invention have been described in detail above, and it is apparent to those skilled in the art that such specific descriptions are merely preferred embodiments, and thus the scope of the present invention is not limited thereto. something to do. Thus, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
본 발명의 추출물을 포함하는 약학조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.One example of the formulation of the pharmaceutical composition comprising the extract of the present invention, but the present invention is not intended to limit it, but is intended to explain in detail.
제제예 1. 산제의 제조Formulation Example 1 Preparation of Powder
천초근 추출물 분말 20 ㎎Cheoncho
유당 100 ㎎
탈크 10 ㎎
상기의 성분들을 혼합하고, 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예 2. 정제의 제조Formulation Example 2 Preparation of Tablet
천초근 추출물 분말 10 ㎎Cheoncho Geun Extract Powder 10mg
옥수수 전분 100 ㎎100 mg corn starch
유당 100 ㎎
스테아린산 마그네슘 2 ㎎2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.
제제예 3. 캅셀제의 제조Formulation Example 3 Preparation of Capsule
천초근 추출물 분말 10 ㎎Cheoncho Geun Extract Powder 10mg
결정성 셀룰로오스 3 ㎎3 mg of crystalline cellulose
락토오스 14.8 ㎎Lactose 14.8 mg
마그네슘 스테아레이트 2 ㎎Magnesium Stearate 2mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전 하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
제제예 4. 주사제의 제조Formulation Example 4 Preparation of Injection
천초근 추출물 분말 10 ㎎Cheoncho Geun Extract Powder 10mg
만니톨 180 ㎎Mannitol 180 mg
주사용 멸균 증류수 2794 ㎎Sterile distilled water for injection 2794 mg
Na2HPO4·12H2O 26 ㎎ Na 2 HPO 4 · 12H 2 O 26 ㎎
통상의 주사제의 제조방법에 따라 1 앰플(2 ㎖)당 상기의 성분 함량으로 제조한다.According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).
제제예 5. 액제의 제조Formulation Example 5 Preparation of Liquid
천초근 추출물 분말 10 ㎎Cheoncho Geun Extract Powder 10mg
이성화당 10 g10 g of isomerized sugar
만니톨 5 g 5 g of mannitol
정제수 적당량Purified water
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고, 레몬향을 적당량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 100 ㎖로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.According to the conventional method of preparing a liquid solution, each component is added and dissolved in purified water, lemon flavor is added to the appropriate amount, the above components are mixed, and then purified water is added to adjust the total amount to 100 ml, and then sterilized by filling in a brown bottle. To prepare.
제제예 6. 건강 음료의 제조Formulation Example 6 Preparation of Healthy Drink
천초근 추출물 분말 10 ㎎Cheoncho Geun Extract Powder 10mg
비타민 C 15 g15 g of vitamin C
비타민 E(분말) 100 g100 g of vitamin E (powder)
젖산철 19.75 gIron lactate 19.75 g
산화아연 3.5 g3.5 g of zinc oxide
니코틴산아미드 3.5 gNicotinamide 3.5 g
비타민 A 0.2 g0.2 g of vitamin A
비타민 B1 0.25 g0.25 g of vitamin B1
비타민 B2 0.3 g 0.3 g of vitamin B2
물 적당량Water
통상의 건강 음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85 ℃에서 교반 가열 후, 만들어진 용액을 여과하여 멸균된 2 ℓ의 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관하여 본 발명에 따른 건강 음료 조성물 제조에 사용한다.After mixing the above components according to a conventional healthy beverage production method, and then stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and refrigerated and stored in the present invention It is used to prepare a healthy beverage composition according to.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층이나 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is a composition suitable for a preferred beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
상술한 바와 같이, 본 발명에 따른 천초근 추출물은 알레르기를 유발하는 비 만세포의 분비작용 및 알레르기의 동물모델에서 알레르기의 유발을 저농도에서 억제함으로써 알레르기 증상을 완화하는 항알레르기 효과를 나타내므로, 알레르기 질환의 예방 및 치료를 위한 약학조성물 또는 건강기능식품으로서 이용가능하다.As described above, the cheoncho root extract according to the present invention exhibits an antiallergic effect of allergy-inducing alleviating allergic symptoms by inhibiting allergen-induced secretion of mast cells and inducing allergy at low concentrations in animal models of allergy. It can be used as a pharmaceutical composition or health functional food for the prevention and treatment of diseases.
또한, 종래의 증상회복 위주의 치료와는 달리 비만세포에서의 알레르기 유발 물질의 분비를 원천적으로 차단함으로써 다양한 부작용을 제거할 수 있는 약학조성물 또는 건강기능식품으로도 유용하게 사용될 수 있을 것이 기대된다.In addition, unlike the conventional symptom recovery-oriented treatment, it is expected that it can be usefully used as a pharmaceutical composition or health functional food that can remove various side effects by blocking the secretion of allergens in mast cells.
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050066830A KR100750873B1 (en) | 2005-07-22 | 2005-07-22 | A pharmaceutical composition comprising the extract of Rubiae Radix for treating or preventing allergic disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050066830A KR100750873B1 (en) | 2005-07-22 | 2005-07-22 | A pharmaceutical composition comprising the extract of Rubiae Radix for treating or preventing allergic disease |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070012037A KR20070012037A (en) | 2007-01-25 |
KR100750873B1 true KR100750873B1 (en) | 2007-08-22 |
Family
ID=38012590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050066830A KR100750873B1 (en) | 2005-07-22 | 2005-07-22 | A pharmaceutical composition comprising the extract of Rubiae Radix for treating or preventing allergic disease |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100750873B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012108746A2 (en) * | 2011-02-11 | 2012-08-16 | 주식회사 한국전통의학연구소 | Composition and cosmetic composition for treating brain cancer comprising rubia cordifolia root extract |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114099396B (en) * | 2022-01-10 | 2023-05-05 | 山东花物堂生物科技有限公司 | Preparation method of radix rubiae extract with whitening effect |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030055678A (en) * | 2001-12-27 | 2003-07-04 | 류종훈 | Composition containing an extract of rubiae radix for protecting brain cells and treating brain stroke |
-
2005
- 2005-07-22 KR KR1020050066830A patent/KR100750873B1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030055678A (en) * | 2001-12-27 | 2003-07-04 | 류종훈 | Composition containing an extract of rubiae radix for protecting brain cells and treating brain stroke |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012108746A2 (en) * | 2011-02-11 | 2012-08-16 | 주식회사 한국전통의학연구소 | Composition and cosmetic composition for treating brain cancer comprising rubia cordifolia root extract |
WO2012108746A3 (en) * | 2011-02-11 | 2012-12-20 | 주식회사 한국전통의학연구소 | Composition and cosmetic composition for treating brain cancer comprising rubia cordifolia root extract |
Also Published As
Publication number | Publication date |
---|---|
KR20070012037A (en) | 2007-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101898688B1 (en) | Composition for preventing, treating or improving muscle atrophy comprising complex extracts | |
US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
CN101612315A (en) | A kind of compound Chinese medicinal preparation that is used to adjust function of human body | |
KR102448542B1 (en) | Composition for relieving menopausal symptom | |
KR100597235B1 (en) | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis | |
KR100824970B1 (en) | Polygoni cuspidati radix extract for allergic disease and process for preparation thereof | |
KR20110127443A (en) | Composition for anti-obesity and antioxidant comprising camellia japonica flower extract as active ingredient | |
KR101045031B1 (en) | A composition comprising fruits of Cudrania tricuspidata for immunopotentiating | |
KR20110019492A (en) | A composition comprising an extract of cudrania tricuspidata having anti-allergic activity | |
KR101729003B1 (en) | Composition For Preventing or Treating Gout Containing Extracts or Fermentation Metabolites of Dendropanax morbiferus | |
KR100522579B1 (en) | Pharmaceutical composition comprising the extracts of scutellaria root and schizandra fruit mixture thereof having an effect of restraint stress | |
KR100750873B1 (en) | A pharmaceutical composition comprising the extract of Rubiae Radix for treating or preventing allergic disease | |
KR102210158B1 (en) | A composition for improving, preventing and treating of arthritis comprising Milk thistle and Achyranthes bidentata Blume | |
KR100750879B1 (en) | A pharmaceutical composition comprising the extract of Meliae Cortex for treating or preventing allergic disease | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
KR101151567B1 (en) | Composition comprising the extract of mixed crude drug showing anti-allergic Effect | |
KR101899555B1 (en) | A composition for improving, preventing and treating arthritis comprising Stewartia koreana extract and Rhus verniciflua stokes extract | |
KR101680013B1 (en) | Pharmaceutical composition for preventing or treating allergic diseases comprising extrat of Pterocarpus indicus Willd as an active ingredient | |
WO2008069604A1 (en) | Composition comprising the mixed herbal extract of aralia cordata thunb. and cimicifuga heracleifolia kom. for preventing and treating inflammatory disease and pain disease | |
KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
KR102128510B1 (en) | Composition comprising extract of Panax ginseng and Liriope platyphylla for preventing or treating learning, cognition or memory disabilities | |
KR20120089045A (en) | A composition comprising powder of amphicarpaea bracteata subsp.edgeworthii(benth.) h.ohashi and the extract thereof for preventing and treating diabetes mellitus and diabetic complication | |
KR101131719B1 (en) | Pulsatilla koreana extracts compositions for treating or preventing inflammatory diseases | |
KR20120008366A (en) | A composition comprising the compound isolated from schisandra chinensis for preventing and treating colitis disease | |
KR100538983B1 (en) | Pharmaceutical composition comprising the crude drug extract for improving liver function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Publication of correction | ||
FPAY | Annual fee payment |
Payment date: 20110803 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20120712 Year of fee payment: 6 |
|
LAPS | Lapse due to unpaid annual fee |